Drug intelligence / Profile preview

Eczemol

Development stage: Unknown
Lead developer: Plymouth Healthcare Products
Modality: Small Molecules
Administration: Oral

Overview

Eczemol is a biochemical homeopathic oral medication developed by Plymouth Pharmaceuticals for the treatment of mild to moderate eczema and atopic dermatitis in both pediatric and adult patients. It is formulated as a tablet containing a combination of Potassium Bromide (Kali Bromatum) 1X, Sulphur 1X, and Nickel Sulphate (Niccolum Sulphuricum) 1X. While the exact mechanism of action is unknown, it is hypothesized to address underlying genetic biochemical defects associated with skin conditions. The medication is typically administered once daily on an empty stomach and can be swallowed whole, chewed, or dissolved in the mouth. It is classified as a prescription homeopathic drug.

Brand names: Eczemol

Beyond the preview

Go deeper on Eczemol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eczemol.

Explore the full profile